Detalhe da pesquisa
1.
ACE inhibitors and angiotensin receptor blockers differentially alter the response to angiotensin II treatment in vasodilatory shock.
Crit Care
; 28(1): 130, 2024 04 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38637829
2.
Renin and Survival in Patients Given Angiotensin II for Catecholamine-Resistant Vasodilatory Shock. A Clinical Trial.
Am J Respir Crit Care Med
; 202(9): 1253-1261, 2020 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32609011
3.
Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock.
Crit Care
; 24(1): 43, 2020 02 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32028998
4.
Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia.
Am J Hematol
; 91(8): 800-5, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27169385
5.
Angiotensin II treatment is associated with improved oxygenation in ARDS patients with refractory vasodilatory shock.
Ann Intensive Care
; 13(1): 128, 2023 Dec 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38103056
6.
Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug.
Blood
; 116(9): 1524-7, 2010 Sep 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-20530289
7.
Regional differences in the treatment of refractory vasodilatory shock using Angiotensin II in High Output Shock (ATHOS-3) data.
J Crit Care
; 50: 188-194, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30553989
8.
A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma.
Clin Cancer Res
; 25(2): 478-486, 2019 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30279233
9.
Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro.
Mol Cancer Ther
; 12(9): 1763-73, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-23832122